Drugs / JNJ-38877618
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT01964872 | Nov 2013 → May 2014 | — | Janssen Cilag N.V./S.A. | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT03138083 | Aug 2017 → May 2020 | neoplasm | Octimet Oncology N.V. | Terminated | No outcome recorded Stop: Business |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | JNJ-38877618 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01964872 ↗ |
| Known as | OMO-1 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03138083 ↗ |
| Action | Inhibit | “OMO-1 is a small molecule inhibitor of the enzymatic activity of the MET receptor tyrosine kinase” NCT03138083 ↗ |
| Modality | Small molecule | “OMO-1 is a small molecule inhibitor of the enzymatic activity of the MET receptor tyrosine kinase” NCT03138083 ↗ |
| Route | Oral | “Single ascending dose administered orally in liquid formulation (Formulation A).” NCT01964872 ↗ |
| Target | MET | “OMO-1 is a small molecule inhibitor of the enzymatic activity of the MET receptor tyrosine kinase” NCT03138083 ↗ |